Targeting renal cell carcinoma with a HIF-2 antagonist

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Nature

• Publication date

  2016-09-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature19796PMID 27595394PMCID PMC5340502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• On‐Target Efficacy of a HIF2α Antagonist in Preclinical Kidney Cancer Models

  2017cited by this paper
• Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

  2017cited by this paper
• On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

  2016cited by this paper
• A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.

  2016cited by this paper
• A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.

  2016cited by this paper
• Structural integration in hypoxia-inducible factors

  2015cited by this paper
• Fructose-1, 6-bisphosphatase opposes renal carcinoma progression

  2014cited by this paper
• HTSeq—a Python framework to work with high-throughput sequencing data

  2014cited by this paper
• Molecular genetics of clear-cell renal cell carcinoma.

  2014cited by this paper
• Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing

  2014cited by this paper
• STAR: ultrafast universal RNA-seq aligner

  2013cited by this paper
• Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications

  2013cited by this paper
• Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor.

  2013cited by this paper
• Allosteric Inhibition of Hypoxia Inducible Factor-2 with Small Molecules

  2013influential reference
• RSeQC: quality control of RNA-seq experiments

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• BAP1 loss defines a new class of renal cell carcinoma

  2012cited by this paper
• A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma

  2012cited by this paper
• HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

  2011cited by this paper
• A complex task? Direct modulation of transcription factors with small molecules.

  2010cited by this paper
• Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor

  2009cited by this paper
• HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses

  2009cited by this paper
• edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

  2009cited by this paper
• Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.

  2008cited by this paper
• Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry

  2008cited by this paper
• MR classification of renal masses with pathologic correlation

  2008cited by this paper
• Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo.

  2007cited by this paper
• HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity.

  2007cited by this paper
• HIF-2 regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth

  2006cited by this paper
• HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth.

  2006cited by this paper
• Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells.

  2006cited by this paper
• Differential Regulation of the Transcriptional Activities of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) and HIF-2α in Stem Cells

  2006cited by this paper
• Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma

  2005cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• Structural basis for PAS domain heterodimerization in the basic helix–loop–helix-PAS transcription factor hypoxia-inducible factor

  2003cited by this paper
• Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

  2002cited by this paper
• Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.

  1997cited by this paper
• A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development.

  1997cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• Mutations of the VHL tumour suppressor gene in renal carcinoma

  1994cited by this paper
• Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

  1994cited by this paper

• Targeting HIF-2α in Colorectal Cancer Reveals a Cholesterol Biosynthesis–Dependent Ferroptotic Vulnerability

  2026cites this paper
• Rhythms of risk: the intersection of clocks, cancer, and chronotherapy

  2026cites this paper
• ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma.

  2026cites this paper
• Cyclin D1 and the resistance landscape of HIF2 inhibition in clear-cell renal cell carcinoma: Insights from a mini-review.

  2026cites this paper
• HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.

  2026cites this paper
• Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group

  2026cites this paper
• Regulatory networks of HIFs in tumor-infiltrating immune cells: From molecular mechanisms to therapeutic implications (Review)

  2026cites this paper
• Targeting HIF‐2α in renal cell carcinoma: Expanding upon belzutifan

  2026influential citation
• Conserved structural motifs in PAS, LOV, and CRY proteins regulate circadian rhythms and are therapeutic targets.

  2026cites this paper
• Amino Acid Metabolic Reprogramming in Clear Cell Renal Cell Carcinoma: Pathogenic Mechanisms and Therapeutic Targeting.

  2026cites this paper
• Surgical management of giant Xp11.2 translocation renal cell carcinoma with multivisceral invasion: a case report of en bloc resection and targeted-immunotherapy success

  2026cites this paper
• Cobalt Chloride Protects Against Intestinal Irradiation‐Induced Injury by Activating the HIF‐2α

  2026cites this paper
• HIF sustain a transcriptional regulatory circuit of EPAS1 expression in renal clear cell carcinoma

  2026cites this paper
• HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma.

  2026cites this paper
• Targeting and dissociating HIF2α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer

  2026cites this paper
• Emerging roles of metabolic biomarkers in renal cell carcinoma: from molecular mechanisms to clinical implications

  2025cites this paper
• Single-cell sequencing technology in renal cancer: insights into tumor biology and clinical application

  2025cites this paper
• Nuclear speckles regulate functional programs in cancer

  2025cites this paper
• HIF Regulates Multiple Translated Endogenous Retroviruses: Implications for Cancer Immunotherapy

  2025cites this paper
• BMAL1 and ARNT enable circadian HIF2α responses in clear cell renal cell carcinoma

  2025influential citation
• BBOX1 restrains TBK1-mTORC1 oncogenic signaling in clear cell renal cell carcinoma

  2025cites this paper
• HIF-2α inhibitors in clear cell renal cell carcinoma: a clinical pharmacy perspective on lipid metabolism, therapeutic management, and resistance strategies

  2025cites this paper
• SPAG6 hypermethylation silences a novel tumor suppressor and inhibits renal cell carcinoma progression via PI3K/AKT/mTOR pathway

  2025cites this paper
• Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma

  2025cites this paper
• A real-world pharmacovigilance study of belzutifan in renal cell carcinoma and von Hippel-Lindau disease: insights from the FDA adverse event reporting system database

  2025cites this paper
• Metabolic Supremacy Fuels Tumor Aggressiveness in Renal Cancer

  2025cites this paper
• Hypoxia Inducible Factor-2α (HIF-2α) Pathway Inhibitors

  2025cites this paper
• RSK4 promotes the metastasis of clear cell renal cell carcinoma by activating RUNX1-mediated angiogenesis

  2025cites this paper
• Endogenous Targeting of Lipid Nanoparticles to Kidney Tumors.

  2025cites this paper
• HIF2-driven PTHrP Causes Cachexia and Hypercalcemia in Kidney Cancer: Treatment with HIF2 Inhibitors

  2025cites this paper
• CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS

  2025cites this paper
• SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers

  2025cites this paper
• Molecular Mechanisms of Drug Resistance in Clear Cell Renal Cell Carcinoma

  2025cites this paper
• The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma

  2025cites this paper
• Biomarker-informed care for patients with renal cell carcinoma

  2025cites this paper
• Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription

  2025cites this paper
• In Pursuit of KI-RADS: Toward a Single, Evidence-based Imaging Classification of Renal Masses.

  2025cites this paper
• Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in Mice

  2025cites this paper
• Interactions Between Non-Coding RNAs and HIF-1alpha in the Context of Colorectal Cancer

  2025cites this paper
• SEPT5 overexpression predicts poor prognosis and promotes progression through feedback regulation of HIF-1α in clear cell renal cell carcinoma.

  2025cites this paper
• Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer

  2025cites this paper
• Landscape of Noncoding RNA in the Hypoxic Tumor Microenvironment

  2025cites this paper
• The Effect of HIF‐2α on the Development of Inflammation

  2025cites this paper
• Dual Inhibition of HIF-1α and HIF-2α as a Promising Treatment for VHL-Associated Hemangioblastomas: A Pilot Study Using Patient-Derived Primary Cell Cultures

  2025cites this paper
• Machine learning-derived cellular senescence index for predicting prognosis and drug sensitivity in patients with renal cell carcinoma

  2025cites this paper
• The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs

  2025cites this paper
• Mitophagy-related gene TRIP13 predicts prognosis and immune response and promotes proliferation and migration in vitro and in vivo of clear cell renal cell carcinoma

  2025cites this paper
• ELOC-mutant renal cell carcinoma: practical diagnostic features and differential considerations

  2025cites this paper
• Integrative multi-omics reveal NSUN2 facilitates glycolysis and histone lactylation-driven immune evasion in renal carcinoma

  2025cites this paper
• CYP1B1 promotes angiogenesis and sunitinib resistance in clear cell renal cell carcinoma via USP5-mediated HIF2α deubiquitination

  2025cites this paper
• Manganese-Doped Nanoparticles with Hypoxia-Inducible Factor 2α Inhibitor That Elicit Innate Immune Responses against von Hippel-Lindau Protein-Deficient Tumors.

  2025cites this paper
• Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy.

  2025cites this paper
• Radiogenomics of Stereotactic Radiotherapy: Genetic Mechanisms Underlying Radiosensitivity, Resistance, and Immune Response

  2025cites this paper
• The RNA demethylase FTO promotes glutamine metabolism in clear cell renal cell carcinoma through the regulation of SLC1A5

  2025cites this paper
• Comparative single‐cell transcriptomic profiling of patient‐derived renal carcinoma cells in cellular and animal models of kidney cancer

  2025cites this paper
• The role of ubiquitination and deubiquitination in urological tumours

  2025cites this paper
• Belzutifan-Associated Hypoxia: A Review of the Novel Therapeutic, Proposed Mechanisms of Hypoxia, and Management Recommendations

  2025cites this paper
• Belzutifan for the treatment of renal cell carcinoma

  2025cites this paper
• HIF-2-dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear Cell Renal Cell Carcinoma.

  2025cites this paper
• Renal surgery following HIF-2α antagonist therapy: Surgical indications, outcomes and growth kinetics.

  2025cites this paper
• Patient-derived organoids reveal hypoxia-driven plasticity and therapeutic vulnerabilities in pheochromocytomas and paragangliomas

  2025cites this paper
• Narrative Review of Von Hippel-Lindau Syndrome: From Discovery to Modern Medical and Surgical Therapies

  2025cites this paper
• Belzutifan for patients with Von Hippel-Lindau (VHL) disease-associated heterogeneous tumors – a retrospective single center analysis

  2025cites this paper
• Tumor Microenvironment: Current Understanding and Therapeutic Implications in Adult and Pediatric Cancers

  2025cites this paper
• Drug Candidate Identification for Renal Cell Carcinoma via Gene Regulatory Module Analysis and Docking Studies

  2025cites this paper
• The novel hydrogen-PT2385-silncARSR nanocomplex impairs tumor angiogenesis and mitochondrial activity in sunitinib-resistant renal cancer

  2025cites this paper
• Development of a Novel HIF-2α PET Tracer for Noninvasive Tumor Hypoxia Imaging

  2025cites this paper
• USP24 stabilizes VDAC2 via deubiquitination to promote apoptosis and ferroptosis in clear cell renal cell carcinoma (ccRCC)

  2025cites this paper
• Targeting of HIF2-driven cachexia in kidney cancer

  2025cites this paper
• Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009-2024).

  2024cites this paper
• HIF-2α Inhibition Disrupts Leukemia Stem Cell Metabolism and Impairs Vascular Microenvironment to Enhance Chronic Myeloid Leukemia Treatment.

  2024cites this paper
• VHL suppresses UBE3B-mediated breast tumor growth and metastasis

  2024cites this paper
• Ameliorating effects of the HIF-2α inhibitor PT2385 on high-altitude polycythemia.

  2024cites this paper
• The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2

  2024cites this paper
• Oral HIF-2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.

  2024cites this paper
• Unconventional mechanism of action and resistance to rapalogs in renal cancer

  2024cites this paper
• Practical management of renal cell carcinoma: integrating current approaches with advances in bone metastasis treatment

  2024cites this paper
• BMAL1-HIF2α heterodimers contribute to ccRCC

  2024cites this paper
• The interplay between the tumor microenvironment and tumor-derived small extracellular vesicles in cancer development and therapeutic response

  2024cites this paper
• Metabolic Reprogramming of Clear Cell Renal Cell Carcinoma and Its Clinical Significance

  2024cites this paper
• BMAL1-HIF2α heterodimers contribute to ccRCC

  2024cites this paper
• Comprehensive bioinformatics analysis of KIF20A as a prognosis biomarker for clear cell renal cell carcinoma.

  2024cites this paper
• Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.

  2024cites this paper
• Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in Leukemia

  2024cites this paper
• CD2AP is a potential prognostic biomarker of renal clear cell carcinoma

  2024cites this paper
• Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer Cells

  2024cites this paper
• VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation

  2024cites this paper
• HIF2α Promotes Cancer Metastasis through TCF7L2-Dependent Fatty Acid Synthesis in ccRCC

  2024cites this paper
• TBC1D5 reverses the capability of HIF-2α in tumor progression and lipid metabolism in clear cell renal cell carcinoma by regulating the autophagy

  2024cites this paper
• Biophysical interplay between extracellular matrix remodeling and hypoxia signaling in regulating cancer metastasis

  2024cites this paper
• VHL governs m6A modification and PIK3R3 mRNA stability in clear cell renal cell carcinomas

  2024cites this paper
• Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis

  2024cites this paper
• MED15 is upregulated by HIF-2α and promotes proliferation and metastasis in clear cell renal cell carcinoma via activation of SREBP-dependent fatty acid synthesis

  2024cites this paper
• A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

  2024cites this paper
• Differential expression and prognostic value of TLR4 in kidney renal clear cell carcinoma.

  2024cites this paper
• Exploring the causal relationship between omega-3 and omega-6 fatty acids and kidney cancer: a Mendelian randomization study

  2024cites this paper
• Hypoxia and its effect on the cellular system

  2024cites this paper
• HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma

  2024cites this paper
• Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma

  2024influential citation
• Poly-3-hydroxybutyrate-co-3-hydroxyvalerate(PHBV)-Polyethylene glycol 20k(PEG20k) as a promising delivery system for PT2399 in the treatment of disc degeneration

  2024cites this paper